Nipah Virus (NiV) – A High-Priority Zoonotic Threat
The Nipah virus (NiV) is a highly pathogenic, emerging zoonotic pathogen that poses a significant public health threat, primarily in South and Southeast Asia. Classified within the genus Henipavirus of the family Paramyxoviridae, NiV is a Biosafety Level 4 (BSL-4) agent due to the lack of licensed treatments or vaccines and its extremely high case fatality rate, which is estimated to range between 40% and 75%. NiV is transmitted to humans from animals and can cause a spectrum of illnesses ranging from asymptomatic infection to acute respiratory disease and fatal encephalitis.
The virus was first identified in 1999 following a large outbreak among pig farmers in Malaysia and Singapore. It is named after the village in Malaysia where the virus was first isolated. The initial outbreak resulted in over 300 cases and more than 100 deaths. Since then, outbreaks have occurred nearly annually in parts of South Asia, particularly Bangladesh and eastern India. The geographical expansion of the virus reservoir has been linked to ecological disruptions, such as deforestation and widespread forest burning, which can prompt the migration of the natural host population, thus increasing the likelihood of spillover events.
Natural Reservoir and Transmission Pathways
The natural reservoir for the Nipah virus is the fruit bat, specifically species belonging to the genus Pteropus, commonly known as ‘flying foxes’ (e.g., Pteropus vampyrus, P. hypomelanus, and P. giganteus). These bats are the asymptomatic natural hosts and can be found throughout Southeast Asia, the South Pacific, and Australia region. NiV is shed by infected bats primarily through their urine and saliva, and also in birth fluids and rectal secretions. The virus is relatively stable and can survive for a few days in the environment and up to seven days in date palm sap kept at 22°C.
NiV transmission to humans occurs via three main pathways. The first is direct animal-to-human transmission. The initial Malaysian outbreak was predominantly associated with unprotected exposure to infected domestic animals, mainly pigs, or their contaminated tissues and secretions. Pigs are considered intermediate hosts, having been infected by bats feeding on fruits or ingesting contaminated water. Transmission has also been reported through contact with infected horses, goats, and cats.
A second route, which has been the most common source of infection in Bangladesh and India, is through contaminated food. This involves the consumption of fruits or fruit products—most notably raw date palm sap—that have been contaminated by the urine or saliva of infected fruit bats, often while they are roosting or feeding. People who climb trees where infected bats often roost also face an increased risk of infection.
The third, and highly significant, route is human-to-human transmission. This spread occurs through close contact with the bodily fluids (respiratory secretions, nasal droplets, urine, or blood) of an infected person. Human-to-human transmission is frequently reported among family members acting as caregivers and in healthcare settings (nosocomial transmission) where infection control measures are inadequate. Patients presenting with severe respiratory symptoms are more likely to transmit the virus through respiratory droplets.
Clinical Manifestations and Disease Progression
The incubation period for Nipah virus infection typically ranges from 4 to 14 days, though an incubation period as long as 45 days has been reported. The disease presentation can be highly variable and is often categorized into two major clinical syndromes: respiratory illness and encephalitis (brain inflammation), with the dominant presentation depending on the specific NiV strain. For instance, the outbreak in Malaysia was characterized primarily by encephalitis, while outbreaks in Bangladesh have featured a higher incidence of severe respiratory disease, including atypical pneumonia and acute respiratory distress syndrome (ARDS).
Initial symptoms are non-specific and resemble a severe flu-like illness, including fever, headache, myalgia (muscle pain), sore throat, cough, vomiting, and dizziness. Respiratory symptoms are present in approximately half of the cases early on. However, in severe cases, the patient’s condition rapidly deteriorates. Neurological signs indicating acute encephalitis—such as drowsiness, disorientation, confusion, brainstem dysfunction, and seizures—can develop, progressing swiftly to a coma within 24 to 48 hours. The virus targets the endothelium of blood vessels, causing a diffuse vasculitis that is particularly prominent in the central nervous system, lungs, kidneys, and spleen, often leading to multi-organ failure in fulminant cases.
Prognosis, Complications, and Management
The high case fatality rate (40%–75%) underscores the severity of Nipah virus infection. The presence of the virus in cerebrospinal fluid is strongly associated with mortality. For those who survive the acute phase of encephalitis, long-term neurological sequelae are common, affecting around 20% of survivors. These residual deficits can include chronic fatigue, personality changes, cognitive impairment, recurrent seizures, and focal neurological signs such as cervical dystonia and ocular motor palsies. Furthermore, a small proportion of survivors can experience a relapse or a delayed-onset of encephalitis, sometimes months or even years post-exposure, which indicates a dormant or latent infection and can have fatal outcomes.
Early diagnosis is challenging because the initial symptoms are non-specific. Diagnosis is typically confirmed using real-time polymerase chain reaction (RT-PCR) testing on throat and nasal swabs, cerebrospinal fluid, urine, or blood during the early stages of illness, and through antibody tests in later stages or for surveillance. Currently, there are no licensed antiviral drugs or vaccines specifically targeting NiV infection. The recommended treatment remains intensive supportive care focused on managing severe respiratory and neurological complications. Experimental treatments, such as the monoclonal antibody m102.4 and the antiviral drug remdesivir, have been explored on a compassionate use basis or in preclinical trials.
Prevention is the cornerstone of public health efforts. Given the transmission routes, preventative measures include practicing good hand hygiene, avoiding close contact with sick animals (especially pigs and bats) or infected people, and crucially, avoiding the consumption of raw date palm sap and fruits or fruit products that show signs of contamination by bat secretions. Strict infection control practices, including the use of appropriate Personal Protective Equipment (PPE) by healthcare workers, are essential to prevent nosocomial and human-to-human transmission during outbreaks.